Moving towards high-dose primaquine or single-dose tafenoquine for Plasmodium vivax treatment in Cambodia: a meeting report from dissemination of results of the EFFORT trial to stakeholders

L Dysoley; S Cassidy-Seyoum; B Adhikari; A Dahal; N Phoumen; S Srey; T Phalla; P Vonn; B Engrkruy; O Sovanarath; H Mengkea; P Rathana; I Makara; PK Heng; Y Heng; H Khlok; K Pong; T Moeng; S Vantha; U Soviet; R Ravuth; V Bunreth; K Vannak; M Sokhann; K Kimmen; K Dy; S Samol; K Lo; N Sokunthea; H Kry; L Kanha; L Naren; S Oum; Y Sovann; R Channavuth; C Bunmeng; J Hughes; H Brindle; Y Hu; S Peng; P Mardi; I Chanry; S Preap; S Heoy; F Sabawoon; T Sokha; P Ringwald; CA Lynch; RN Price; R Tripura; L von Seidlein; A Devine; K Thriemer

Journal article

Moving towards high-dose primaquine or single-dose tafenoquine for Plasmodium vivax treatment in Cambodia: a meeting report from dissemination of results of the EFFORT trial to stakeholders

L Dysoley, S Cassidy-Seyoum, B Adhikari, A Dahal, N Phoumen, S Srey, T Phalla, P Vonn, B Engrkruy, O Sovanarath, H Mengkea, P Rathana, I Makara, PK Heng, Y Heng, H Khlok, K Pong, T Moeng, S Vantha, U Soviet Show all

Malaria Journal | Published : 2026

DOI: 10.1186/s12936-025-05691-1

Abstract

Cambodia has targeted malaria elimination by 2025. As the malaria burden has decreased in Cambodia, transmission has become more focal, and Plasmodium vivax has become the predominant species. The recurrent nature of P. vivax, due to its dormant liver stages causing relapses, is the main obstacle to malaria elimination in Cambodia. In 2021, Cambodia’s National Center for Parasitology, Entomology and Malaria Control (CNM) rolled out low-dose 14-day primaquine (total dose 3.5 mg/kg) supported by point-of-care quantitative testing for glucose-6-phosphate dehydrogenase deficiency. However, this treatment is limited by poor adherence to its prolonged duration and suboptimal efficacy of the low to..

View full abstract